Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. https://doi.org/10.3322/caac.21660..
DOI: 10.3322/caac.21660
Ferlay J., Colombet M., Soerjomataram I., Parkin D.M., Piñeros M., Znaor A., Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021. https://doi.org/10.1002/ijc.31937..
DOI: 10.1002/ijc.31937
Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.). Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М.; 2022. 252 с.
Torricelli F., Sauta E., Manicardi V., Mandato V.D., Palicelli A., Ciarrocchi A., Manzotti G. An Innovative Drug Repurposing Approach to Restrain Endometrial Cancer Metastatization. Cells. 2023;12(5):794. https://doi.org/10.3390/cells12050794..
DOI: 10.3390/cells12050794
Nagao S., Nishio S., Michimae H., Tanabe H., Okada S., Otsuki T. et al. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol. 2013;131(3):567–573. https://doi.org/10.1016/j.ygyno.2013.09.021..
DOI: 10.1016/j.ygyno.2013.09.021
Mandato V.D., Palicelli A., Torricelli F., Mastrofilippo V., Leone C., Dicarlo V. et al. Should Endometrial Cancer Treatment Be Centralized? Biology (Basel). 2022;11(5):768. https://doi.org/10.3390/biology11050768..
DOI: 10.3390/biology11050768
Mandato V.D., Palicelli A., Torricelli F., Mastrofilippo V., Leone C., Dicarlo V. et al. Should Endometrial Cancer Treatment Be Centralized? Biology (Basel). 2022;11(5):768. https://doi.org/10.3390/biology11050768..
DOI: 10.3390/biology11050768
Heffernan K., Nikitas F.S., Shukla U., Camejo H.S., Knott C. Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis. Gynecol Oncol. 2022;166(2):317–325. https://doi.org/10.3390/biology11050768..
DOI: 10.3390/biology11050768
Kelkar S.S., Prabhu V.S., Zhang J., Corman S., Macahilig C., Rusibamayila N. et al. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States. Gynecol Oncol Rep. 2022;42:101026. https://doi.org/10.1016/j.gore.2022.101026..
DOI: 10.1016/j.gore.2022.101026
Mevius A., Karl F., Wacker M., Welte R., Krenzer S., Link T. et al. Real-world treatment of German patients with recurrent and advanced endometrial cancer with a post-platinum treatment: a retrospective claims data analysis. J Cancer Res Clin Oncol. 2023;149(5):1929–1939. https://doi.org/10.1007/s00432-022-04183-y..
DOI: 10.1007/s00432-022-04183-y
Vistad I., Bjørge L. Advanced endometrial cancer: New medical treatment options on the horizon. Acta Obstet Gynecol Scand. 2023;102(2):128–129. https://doi.org/10.1111/aogs.14499..
DOI: 10.1111/aogs.14499
Paleari L. New Strategies for Endometrial Cancer Detection and Management. Int J Mol Sci. 2023;24(7):6462. https://doi.org/10.3390/ijms24076462..
DOI: 10.3390/ijms24076462
Abdol Manap N., Ng B.K., Phon S.E., Abdul Karim A.K., Lim P.S., Fadhil M. Endometrial Cancer in Pre-Menopausal Women and Younger: Risk Factors and Outcome. Int J Environ Res Public Health. 2022;19(15):9059. https://doi.org/10.3390/ijerph19159059..
DOI: 10.3390/ijerph19159059
Boeckstaens S., Dewalheyns S., Heremans R., Vikram R., Timmerman D., Van den Bosch T., Verbakel J.Y. Signs and symptoms associated with uterine cancer in pre- and postmenopausal women. Heliyon. 2020;6(11):e05372. https://doi.org/10.1016/j.heliyon.2020.e05372..
DOI: 10.1016/j.heliyon.2020.e05372
Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.). Состояние онкологической помощи населению России в 2021 году. М.; 2022. 239 с. Режим работы: https://oncology-association.ru/wp-content/uploads/2022/05/sostoyanie-onkologicheskoj-pomoshhi-naseleniyu-rossii-v-2021-godu.pdf.https://oncology-association.ru/wp-content/uploads/2022/05/sostoyanie-onkologicheskoj-pomoshhi-naseleniyu-rossii-v-2021-godu.pdf
Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.). Состояние онкологической помощи населению России в 2021 году. М.; 2022. 239 с. Режим работы: https://oncology-association.ru/wp-content/uploads/2022/05/sostoyanie-onkologicheskoj-pomoshhi-naseleniyu-rossii-v-2021-godu.pdf.https://oncology-association.ru/wp-content/uploads/2022/05/sostoyanie-onkologicheskoj-pomoshhi-naseleniyu-rossii-v-2021-godu.pdf
Neri M., Peiretti M., Melis G.B., Piras B., Vallerino V., Paoletti A.M. et al. Systemic therapy for the treatment of endometrial cancer. Expert Opin Pharmacother. 2019;20(16):2019–2032. https://doi.org/10.1080/14656566.2019.1654996..
DOI: 10.1080/14656566.2019.1654996
Makker V., Taylor M.H., Aghajanian C., Oaknin A., Mier J., Cohn A.L. et al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2020;38(26):2981–2992. https://doi.org/10.1016/j.gore.2021.100840..
DOI: 10.1016/j.gore.2021.100840
Нечушкина В. М., Коломиец Л. А., Кравец О. А., Морхов К. Ю., Новикова Е. Г., Новикова О. В. и соавт. Практические рекомендации по лекарственному лечению рака тела матки и сарком матки. Злокачественные опухоли. 2022;12(3s2-1):260–275. https://doi.org/10.18027/2224-5057-2022-12-3s2-260-275.
DOI: 10.18027/2224-5057-2022-12-3s2-260-275
Oaknin A., Bosse T.J., Creutzberg C.L., Giornelli G., Harter P., Joly F. et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(9):860–877. https://doi.org/10.3390/jcm11226765..
DOI: 10.3390/jcm11226765
Румянцев А.А. Рациональная последовательность терапии распространенного и метастатического рака эндометрия. Опухоли женской репродуктивной системы. 2022;18(2):119–126. https://doi.org/10.17650/1994-4098-2022-18-2-119-126..
DOI: 10.17650/1994-4098-2022-18-2-119-126
O’Malley D.M., Bariani G.M., Cassier P.A., Marabelle A., Hansen A.R., De Jesus Acosta A. et al. Рembrolizumab in Patients With Microsatellite Instability – High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. J Clin Oncol. 2022;40(7):752–761. https://doi.org/10.1200/JCO.21.01874..
DOI: 10.1200/JCO.21.01874
Barrios C., de Lima Lopes G., Yusof M.M., Rubagumya F., Rutkowski P., Sengar M. Barriers in access to oncology drugs – a global crisis. Nat Rev Clin Oncol. 2023;20(1):7–15. https://doi.org/10.1038/s41571-022-00700-7..
DOI: 10.1038/s41571-022-00700-7
Кислов Н.В., Нестеров П.В., Белоногов С.Б. Практические аспекты применения клинических рекомендаций в онкологии. Медицинские технологии. Оценка и выбор. 2020;(2):43–49. https://doi.org/10.17116/medtech20204002143..
DOI: 10.17116/medtech20204002143
Spencer R.J., Rice L.W., Ye C., Woo K., Uppal S. Disparities in the allocation of research funding to gynecologic cancers by Funding to Lethality scores. Gynecol Oncol. 2019;152(1):106–111. https://doi.org/10.1016/j.ygyno.2018.10.021..
DOI: 10.1016/j.ygyno.2018.10.021
Restaino S., Paglietti C., Arcieri M., Biasioli A., Della Martina M., Mariuzzi L. et al. Management of Patients Diagnosed with Endometrial Cancer: Comparison of Guidelines. Cancers (Basel). 2023;15(4):1091. https://doi.org/10.3390/cancers15041091..
DOI: 10.3390/cancers15041091
Restaino S., Paglietti C., Arcieri M., Biasioli A., Della Martina M., Mariuzzi L. et al. Management of Patients Diagnosed with Endometrial Cancer: Comparison of Guidelines. Cancers (Basel). 2023;15(4):1091. https://doi.org/10.3390/cancers15041091..
DOI: 10.3390/cancers15041091
Сапунова Т.А. Анализ проблем демографической ситуации Краснодарского края. Инновационная экономика: перспективы развития и совершенствования. 2021;(3):161–166. Режим доступа: https://elibrary.ru/contents.asp?id=45797694.https://elibrary.ru/contents.asp?id=45797694
Сапунова Т.А. Анализ проблем демографической ситуации Краснодарского края. Инновационная экономика: перспективы развития и совершенствования. 2021;(3):161–166. Режим доступа: https://elibrary.ru/contents.asp?id=45797694.https://elibrary.ru/contents.asp?id=45797694
Makker V., Colombo N., Casado Herráez A., Santin A.D., Colomba E., Miller D.S. et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med. 2022;386(5):437–448. https://doi.org/10.1016/j.gore.2022.101002..
DOI: 10.1016/j.gore.2022.101002
Stinton C., Fraser H., Al-Khudairy L., Court R., Jordan M., Grammatopoulos D., Taylor-Phillips S. Testing for lynch syndrome in people with endometrial cancer using immunohistochemistry and microsatellite instability-based testing strategies – A systematic review of test accuracy. Gynecol Oncol. 2021;160(1):148–160. https://doi.org/10.1016/j.ygyno.2020.10.003..
DOI: 10.1016/j.ygyno.2020.10.003
Duraturo F., Liccardo R., De Rosa M., Izzo P. Genetics, diagnosis and treatment of Lynch syndrome: Old lessons and current challenges. Oncol Lett. 2019;17(3):3048–3054. https://doi.org/10.3892/ol.2019.9945..
DOI: 10.3892/ol.2019.9945
Liu L., Habeshian T.S., Zhang J., Peeri N.C., Du M., De Vivo I., Setiawan V.W. Differential trends in rising endometrial cancer incidence by age, race, and ethnicity. JNCI Cancer Spectr. 2023;7(1):pkad001. https://doi.org/10.1093/jncics/pkad001..
DOI: 10.1093/jncics/pkad001